Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.28 | N/A | -5.46% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.28 | N/A | -5.46% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on pipeline development and is optimistic about future prospects. They acknowledged the challenges but emphasized their commitment to growth.
Management highlighted ongoing efforts to advance their pipeline.
They expressed confidence in their long-term strategy despite the current EPS miss.
The earnings report indicates that BioCryst Pharmaceuticals is still facing challenges, as evidenced by the EPS miss. However, the stock rose by 1.56%, suggesting that investors may be optimistic about the company's long-term strategy and pipeline developments. The lack of revenue figures and guidance leaves some uncertainty, but the positive stock reaction indicates a degree of investor confidence.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERICAN INTL GROUP
May 6, 2019